Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
HNRNPU K181 Lactylation in Cervical Cancer
2026-08-26
This Advanced Science study identifies HNRNPU lysine 181 lactylation as a non-histone regulatory mechanism that connects lactate accumulation with PHGDH-dependent serine biosynthesis in cervical cancer. The findings link a post-translational modification switch to RNA stability, redox balance, nucleotide production, tumor growth, and a pharmacological response to Pazopanib.
-
TMEM16F Scrambling Links Ferroptosis to Tumor Immunity
2026-08-25
Yang et al. identify TMEM16F-mediated plasma-membrane phospholipid scrambling as a late-stage suppressor of ferroptotic membrane failure. The study further shows that disabling this repair-like response promotes lytic death, danger-signal release, slower tumor growth, and stronger responses to PD-1 blockade in preclinical models.
-
Hesperadin: Aurora B Kinase Workflow Guide
2026-08-24
Hesperadin is an ATP-competitive Aurora B kinase inhibitor for dissecting histone H3 phosphorylation, chromosome segregation, cytokinesis, and polyploidization. This practical guide combines cell-based workflows with checkpoint-complex controls so researchers can distinguish Aurora-driven phenotypes from direct effects on MCC disassembly.
-
Fluoxetine HCl: Mechanism and Research Workflows
2026-08-24
Fluoxetine HCl is a selective serotonin reuptake inhibitor used to interrogate serotonin transport, 5-HT2C signaling, neurogenesis, and reward-related behavior. Its acute molecular effects should be separated from developmental SSRI exposure, which is associated with persistent motivational phenotypes in preclinical models.
-
REV1–DHX36 Control of G-Quadruplex Replication
2026-08-23
A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The findings establish a two-tier mechanism for G4 tolerance and connect REV1 deficiency with increased ATM/ATR signaling and sensitivity to G4-stabilizing agents.
-
PR-619 for DUB Inhibition Workflows
2026-08-22
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for separating DUB-dependent ubiquitin accumulation from direct proteasome blockade. This guide translates its chemistry into practical workflows for ubiquitination pathway research, autophagy assays, cancer biology, and carefully bounded immuno-oncology experiments.
-
CMA Decline, SERCA Dysfunction, and Age-Related Myopathy
2026-08-21
This Nature Metabolism study establishes chaperone-mediated autophagy (CMA) as an active regulator of skeletal muscle maintenance rather than a passive lysosomal pathway. Using reporter, genetic, proteomic, physiological, and human-tissue analyses, the authors connect age-related CMA loss to impaired SERCA turnover, calcium dysregulation, muscle weakness, and progressive myopathy.
-
MG-132 (Z-LLL-al) in LUAD Proteasome Workflows
2026-08-20
MG-132 (Z-LLL-al) provides an acute, cell-permeable way to test whether proteasome-dependent protein turnover contributes to LUAD phenotypes. This workflow-focused guide connects PSMA4–p53 biology with apoptosis assays, cell cycle arrest studies, ROS measurements, and practical troubleshooting.
-
RQ3025: Broad-Spectrum mRNA Vaccine Preclinical Study
2026-08-20
This 2024 preclinical study evaluates RQ3025, a bivalent mRNA vaccine designed around conserved and variant-associated SARS-CoV-2 spike mutations. Across mice, hamsters, and rats, the vaccine generated broad neutralizing activity, protected rats from several variants, induced a Th1-biased response, and showed no apparent organ pathology in a high-dose safety assessment.
-
Sodium Ascorbate Workflows for Cancer Research
2026-08-19
Sodium Ascorbate provides a practical ROS-focused intervention for glioblastoma, prostate cancer, and broader tumor-cell assays. This guide connects solvent handling, viability and motility workflows, and immune-biomarker stratification while clearly separating established product evidence from exploratory applications.
-
S1P/S1PR3 Drives Neuronal Apoptosis After ICH
2026-08-19
The reference study identifies an S1P–S1PR3 axis that links post-hemorrhagic inflammation with neuronal apoptosis through TNF-α, PI3K/AKT-associated signaling, and cleaved caspase-3. Its mouse and HT22-cell experiments position S1PR3 as a mechanistic and potentially targetable component of secondary brain injury after intracerebral hemorrhage.
-
Dorsomorphin 2HCl: From AMPK Probe to Translation
2026-08-18
Dorsomorphin 2HCl is more than a routine AMPK inhibitor: it is a pharmacological stress test for causal metabolism research. This thought-leadership guide connects the compound’s AMPK and BMP activity with hepatic steatosis, osteogenesis, hepcidin expression regulation, formulation strategy, and translational decision-making.
-
Cy5 Hydrazide for Carbonyl Labeling
2026-08-18
Cy5 hydrazide provides a far-red strategy for protein carbonylation labeling, glycoprotein analysis, and aldehyde/ketone biomolecule labeling. This article explains how to use its chemistry as an analytical bridge for validating oxidative stress and nanoparticle–cell interaction studies.
-
Ionic Polyphosphazene–Protein Formulations
2026-08-17
Andrianov and colleagues developed soluble and nanoparticulate ionic polyphosphazene systems that assemble with lysozyme near physiological pH, with spermine-mediated cross-linking used to tune formulation behavior. The study shows that nanoparticle architecture, rather than protein integrity alone, strongly influences cellular enzyme presentation and activity.
-
MG-262: Applied Proteasome Inhibition Workflows
2026-08-17
MG-262 enables reversible, cell-permeable control of proteasome chymotryptic activity for mechanistic studies of ubiquitin accumulation, apoptosis, cell-cycle regulation, and osteoclast biology. This workflow connects acute proteasome perturbation with emerging skeletal-muscle proteostasis research while emphasizing controls, washout experiments, and assay-specific troubleshooting.